Jacobs Levy Equity Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Jacobs Levy Equity Management’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-509,225	Closed	-$3.11M	–	1143
2021 Q3	$3.11M	Sell	509,225 -385,389	-43%	-$2.4M	0.02%	532
2021 Q2	$7.36M	Buy	894,614 +120,552	+16%	+$1.03M	0.05%	359
2021 Q1	$6.93M	Buy	774,062 +428,656	+124%	+$4.91M	0.05%	359
2020 Q4	$3.99M	Buy	+345,406	New	+$4.01M	0.04%	437
2016 Q4	–	Sell	-18,400	Closed	-$360K	–	1093
2016 Q3	$360K	Sell	18,400 -10,400	-36%	-$176K	0.01%	772
2016 Q2	$431K	Sell	28,800 -7,880	-21%	-$99K	0.01%	794
2016 Q1	$337K	Buy	+36,680	New	+$445K	0.01%	833
2015 Q3	–	Sell	-9,900	Closed	-$217K	–	882
2015 Q2	$217K	Buy	+9,900	New	+$200K	﹤0.01%	715

Jacobs Levy Equity Management's FLXN Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 509,225 shares — an estimated $3.11M sold.

Jacobs Levy Equity Management first reported a position in FLXN in Q2 2015 and held it in 8 quarters. The position peaked at $7.36M in Q2 2021. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

Jacobs Levy Equity Management reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 509,225 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $3.11M.
Jacobs Levy Equity Management first reported a position in Flexion Therapeutics, Inc. in Q2 2015 and held it in 8 quarters.
Jacobs Levy Equity Management's Flexion Therapeutics, Inc. position peaked at $7.36M in Q2 2021.
1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.